Regarding the sequence of AD biomarker changes, most studies do not show significant sex differences in amyloid (CSF Aβ42/40 ratio), tau (CSF p-tau181, t-tau levels), or markers of neurodegeneration, with two exceptions: A study from the Colombian Kindred found that female carriers exhibited a greater increase in plasma NfL levels compared to male carriers, but no significant differences in p-tau217 levels. The gene discussed is MAPT; the disease is Alzheimer disease.